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Summary.-Transplanted syngeneic osteosarcomas (induced by 32p in DA rats)
grew significantly larger in DA rats receiving a simultaneous transplant of allogeneic
osteosarcoma than in rats receiving syngeneic tumour only (P < 0.01). Two other
malignant allogeneic tumours, and allogeneic spleen cells, did not alter the growth of
the transplanted syngeneic osteosarcomas. When the allogeneic osteosarcoma was
given 7 days before the syngeneic tumour, the reverse effect (retardation) occurred.
When given 7 days after the syngeneic tumour cells, the effect on both syngeneic
and allogeneic tumour growth was variable. Some possible reasons for these
findings are discussed, and the argument is presented that immunological pheno-
nema are involved in the reaction.
TRANSPLANTATION of allogeneic
tumours has been demonstrated to sup-
press growth of spontaneous, viral or
chemically induced tumours in a number
of experimental animal studies (Sjogren,
1961; Klein, Sjogren and Klein, 1962;
Britton, 1971; Usubuchi et al., 1972;
Kobayashi et al., 1974). We report here
evidence that osteosarcoma allografts may,
under certain conditions, actually enhance
growth of a radiation-induced syngeneic
osteosarcoma.
MATERIALS AND METHODS
Animals.-Male DA rats, shown to be
inbred by cross skin grafting, and weighing
approximately 250 g, were used.
Tumours.-The osteosarcomas were in-
duced by 32p in DA and Wistar rats as
previously described (Geddes-Dwyer et al.,
1974) and maintained by serial transplant-
ation in syngeneic animals. The 2 osteosar-
comas in DA rats (designated F and G) were
non-ossifying, very cellular and had a mini-
mum of matrix. Tumour F was used from
20th to 55th transplant generation, and
tumour G from 22nd to 50th. The Wistar
osteosarcoma, used as allograft, was osteo-
genic and was of 22nd to 24th generation.
Two other allogeneic tumours, namely a
hepatoma (Buffalo rat-Morris hepatoma
5123C, transplant generation unknown) and
a spontaneous non-epithelial anaplastic
" mouth " tumour (Wistar rat, 1st to 9th
transplant generations), were used in one
series of experiments (Table III). Tumour
cells were separated enzymatically with
pronase (2 mg/ml-Calbiochem) and DNAase
(125 yg/ml Sigma DN-25).
Allogeneic spleen cells. Spleens were re-
moved from normal adult Wistar rats and
finely minced with razor blades, in Eagle's
minimal essential medium (MEM) buffered
with Hepes. The dissociated cells were
pipetted off, centrifuged and washed twice in
MEM. They were then suspended in Dul-
becco's modified Eagle's medium (DME)
buffered with Hepes and containing 10%
foetal calfserum.
Plan of experimnents. Three series of
experiments were carried out, as shown in the
tables. When using cells from tumour F,
either 2 or 3 x 106 cells were given as a s.c.
inoculum into the flank, but where cells from
Address for correspondence: Dr V. Geddes-Dwyer, Department of Pathology, University of Sydney,
N.S.W. 2006, Australia.
* Present address: Kanematsu Institute, Sydney Hospital, Sydney, N.S.W. 2000.ALLOGRAI'TS ENHANCE SYNGENEIC OSTEOSARCOMAS
czzvvyyYYY Y
o jo0 oo
LIC~~~~~
0- 0 IC0
II
-Z -H~~~A 4 H H-
= ¢ V V V VV V V V
1. oc X D <
;Y e ~eq - eq
CC.~~~~~~~~~~~~~~,
_ _ ^ C ~Oc CZ
CD
; - ; ; ;
~~0 0
- :4
. id
'C; °. Q
O
..t
C
0
X
0
.;
Ow
ekt
o8 48.1c -; ac
- oeq ;. jjc
CD
-, V
C~~~~~~~~~~~~~~.e
..... ...0
C, ° C.
3E-
C _
_:. -Z_
= t _ _
CB :3 t
C)
'
-H _
C T 3 e:: = < ~~~~~0
r
t-
C"
c- >;
fE~
-
C c
ci
n -'
10
eq
0D
87
0 ;
V
x
0o
0NV. GEDDES-DWYER, P. IHfERSEY AND D. A. CAMERON
tumour G were used, the inoculum was either
15 or 3 x 106 cells. Spleen cell inocula
consisted of 3 x 108 cells. Three blocks of
allogeneic osteosarcoma (1 mm3) were used
instead of the injections of 3 x 106 Wistar
tumour cells in some animals (Table IV).
When the DA and Wistar cells were given in
the same flank, 2 separate adjacent injections
were used. All rats were killed after 21 days
and the tumours dissected free from adherent
tissues and weighed.
RESUILTS
Over the 3-year period during which
these experiments were carried out, the
injection of 3 x 106 osteosarcoma cells
has resulted in a gradual reduction in the
weight of resultant syngeneic tumour.
This can be seen from Table I, in which
the experiments are presented in chrono-
logical order. At present we are unable
to explain this phenomenon. When the
syngeneic tumour was given simultane-
ously with allogeneic osteosarcoma (on
the same or opposite side, Tables I and II),
the syngeneic weight was significantly
greater (ipsilateralP < 0 01, contralateral
P < 0.05) than in animals bearing syn-
geneic tumours only. The other allo-
geneic tumours (Buffalo rat hepatoma and
spontaneous Wistar mouth tumour) failed
to alter syngeneic tumour weight appreci-
ably (Table III). Allogeneic spleen cells,
given either simultaneously (Table II)
or 7 days before the syngeneic osteosar-
coma (Table IV) also had no effect on the
syngeneic tumours.
Treatment of DA rats with allogeneic
osteosarcoma 7 days before giving syn-
geneic tumour caused a significant re-
duction (P < 0-01) in syngeneic tumour
weight when compared with the weights of
syngeneic tumours in the untreated con-
trols (Table IV). This applied whether
the tumour allograft cells were given
within their matrix (allograft blocks) or as
a suspension.
In the groups of rats receiving allo-
geneic tumour 7 days after the syngeneic
tumour had been transplanted, increase in
TABLE III.-Weight (in g) at 21 Days of Syngeneic Osteosarcoma (from Tumour F:
2 X 106 Cell8) Without and With AUogeneic Tumours Transplanted Simultanex ly
a
Syngeneic only
o
-No.
b
Syngeneic & allogeneic
osteosarcoma
(ipsilateral)
AN
-No.
c
Syngeneic plus allogeneic
hepatoma
(ipsilateral)
No.
d
Syngeneic plus allogeneic
" mouth " tumour
(ipsilateral)
No.
of of of of
rats Mean s.e. rats Mean s.e. rats* Mean s.e. rats* Mean s.e.
12 0-98 0-47 12 3-65±0 44 12 1-32-+-0-32 12 0-80±-0-28 Student's t test. P (a & b) < 0 05, (a & c) and (a & d) not significant.
* An additional 12 rats received allografts of either hepatoma or "mouth " tumour alone, which did
not take.
TABLE IV.-Weight (in g) at 21 Days of Syngeneic Tumour (from Tumour F: 2 x 106
Cell) Without and Wlith either AUogeneic Spleen Cells or Osteo8arcoma 7 days before the
Syngeneic Transplant
b c d
Svngeneic pretreated with Syngeneic pretreated with Syngeneic pretreated with
a 3 x 10' allogeneic 3 x 10' allogeneic allogeneic osteosarcoma
Syngeneic only spleen cells osteosarcoma cells blocks
A_ A A A
-No. No. No. No.
of of of of
rats* Mean s.e. rats Mean s.e. rats Mean s.e. rats Mean s.e.
10 078±0-10 10 -l0.81±0.14 10 0-450-10 10 0 404-010
Student's t test. P (a & b) not significant, (a & c) < 0-01, (a & d) < 0-01.
* An additional 10 rats received allogeneic osteosarcoma alone which did not take.
88ALLOGRAYTS ENHANCE SYNGENEIC OSTEOSARCOMAS
syngeneic tumour weight was noted in 6/9
rats. Allogeneic osteosarcoma was not
rejected by 21 days in rats receiving this
syngeneic tumour pretreatment. Histo-
logical examination of the site of the
allogeneic transplant revealed viable
Wistar tumour cells both within the
matrix and at the peripherv ofthe Wistar
osteosarcoma (Fig. 1). In the groups
where allogeneic tumour cells or blocks
were given alone, at the same time or
before the svngeneic tumour, histological
sections showed complete rejection (Fig. 2).
The histological appearance of this bone-
forming osteosarcoma could not have been
confused with the non-bone-forming DA
svngeneic tumour (Fig. 3).
DISCUSSION
In these experiments, simultaneous
transplantation of syngeneic and allo-
geneic osteosarcomas resulted in an in-
crease in weight of the syngeneic tumour
rather than inhibition of growth as
described by previous authors (Sjogren,
1961; Klein, Sjogren and Klein, 1962;
Britton, 1971; Usubuchi ed al., 1972;
Kobayashi et al., 1974). This enhance-
ment wa,s specific, in that it was produced
by osteosarcoma allografts but not by
allografts of spleen cells or of cells of 2
other malignant tumours (not osteosar-
comas). Thi strongly suggest that
immune phenomena were concerned, but
the precise mechanism involved is not
clear. Allografts have been shown pre-
viouslv to result in enhanced antibody
responses to " weak" antigens present
on allografts in chickens (Schierman and
McBride, 1967; McBride and Schierman,
1973). We have found evidence for the
presence of a common tumour antigen on
32P-induced osteosarcoma (Geddes-Dwyer,
Hersey and Cameron, in preparation) and
it is therefore possible that the allo-
antigens have resulted in enhanced anti-
body production to this common tumour
antigen by a similar " natural carrier"
effect.
FIG. 1. Wistar osteosarcoma after 21 days in a DA rat pretreated with syngeneic osteosarcoma 7 days
before allografting. x 25. Inset: Viable tumour cells enclosed in bony matrix. x 250.
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FIG. 2.-Wistar osteosarcoma rejected after 21 days in a DA rat simultaneously grafted with syngeneic
osteosarcoma. x 40. Inset: Bony matrix devoid ofviable tumour cells. x 250.
FIG. 3.-DA syngeneic osteosarcoma. x 100. Inset: Anaplastic cells without bony matrix. x 250.
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Arole fortumour antigen inthegrowth-
enhancing effect in our studies is suggested
by the observation that allogeneic osteo-
sarcoma resulted in significantly increased
weight only when given in the presence of
syngeneic tumour. When the allograft
was given before the syngeneic tumour,
the animals were protected against tumour
growth. These results are consistent with
the proposal that tumour enhancement is
the result of immune complexes of anti-
body and tumour antigen rather than
humoral antibody alone (Sjogren et al.,
1971; Baldwin, Price and Robins, 1972).
Complexes of antibody and tumour anti-
gen may also have been responsible for
the prolonged life of allogeneic tumours in
rats, only when given syngeneic tumour
7 days prior to allografting. It is possible
that cell-mediated immunity directed
against tumour antigens on the allograft
surface was inhibited by complexes of
tumour antigen and antibody already
present at a significant level at the time of
allografting.
Our findings of increased syngeneic
tumour weight in the presence of allo-
geneic tumour given simultaneously, and
to a less extent 7 days after the syngeneic
tumour was transplanted, may have
practical clinical implications. Immuni-
zation with allogeneic tumour cells has
been carried outinseveralclinical immuno-
therapy trials (Mathe et al., 1972;
Britton, 1971; Crowther et al., 1973;
Romsdahl and Cox, 1973). Our findings
indicate that the use of tumour allografts
for immunotherapy of human subjects
should be treated with caution.
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